Lenacapavir shows high efficacy in HIV prevention clinical trials

Lenacapavir, a new medication used for pre-exposure prophylaxis (PrEP), is showing significant promise in preventing HIV infection. Unlike traditional daily pills, lenacapavir is administered via an injection into the abdomen that releases slowly into the body, requiring only two doses per year.

Clinical trials known as PURPOSE 1 and PURPOSE 2 have yielded unprecedented results. An independent monitoring committee determined the drug was so effective that the randomized phases of both trials should be stopped early. Following these results, researchers offered the medication to participants in the placebo groups of the studies.

The drug addresses two primary challenges in HIV prevention: efficacy and adherence. By moving away from daily oral regimens to a twice-yearly injection, it reduces the barriers to consistent protection for HIV-negative individuals.